Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationServices · the whole catalogue
All services, side by side
What each one is, who it is for, when it applies, and what it cannot do. In one table, so you do not have to open six pages to compare two things.
What, who, when
Everything, in one table
Six product families, fourteen ways in. The table below is the whole catalogue in one place, so the question “what is the difference between these two” does not require opening six pages.
| Service | What it is | Who it is for | When | Sample | What you get |
|---|---|---|---|---|---|
| Signal | One question, answered by a person on WhatsApp | Anyone, at any stage | Any time. Start here if unsure | None | A human-guided reply within four hours, free |
| Navigation | Your existing records turned into a clarity timeline | Anyone whose paperwork has outgrown them | Before a decision, or before a second opinion | Existing records | A timeline and roadmap you can hand to any clinician |
| Blueprint Care | The decision report and a dedicated clinical team | Anyone facing a treatment decision | At diagnosis, or when treatment changes | Comes with a Signature test or Decipher | A ranked, evidence-tiered plan signed by a tumour board |
| Decipher | Interpretation of sequencing done elsewhere | Anyone already tested but not answered | When you hold a report you cannot act on | Your existing data. No new sample | Full interpretation and board sign-out, without resequencing |
| Decipher Plus | Topping up only the gaps, then interpreting | Where an earlier panel missed something material | When prior testing was too narrow | Existing data plus a targeted top-up | The same report, with the gap filled rather than the test repeated |
| Signature STb | A 33-gene panel from a blood draw | A focused first molecular question | Before a treatment decision | Blood | Variants, therapy matching and a signed decision report |
| Signature STb O | A 118-gene panel from a blood draw | Broader profiling without tissue | Before a treatment decision | Blood | Wider coverage including fusion genes |
| Signature STb O+ | A 523-gene comprehensive panel | When the whole molecular picture matters | Advanced disease, or a complex decision | Blood | Comprehensive profiling with TMB, MSI and pharmacogenomics |
| Signature STt O | Comprehensive profiling from tissue | Where a tumour block already exists | When tissue is available and adequate | An existing FFPE tissue block | Tissue-based comprehensive profiling |
| Signature BML+ and BLL+ | Profiling for blood cancers, 600+ genes | Myeloid and lymphoid disease | At diagnosis, and again at relapse | Blood or bone marrow | Leukaemia-specific molecular characterisation |
| Sentinel | Serial monitoring while treatment runs | Anyone on active treatment | Every few weeks or months, alongside scans | Blood, repeated | A trend line showing response and emerging resistance |
| Clear | Surveillance after curative-intent treatment | Anyone who has finished treatment | On a schedule, for years afterwards | Blood, repeated | Molecular residual disease surveillance |
| Heritage Core | A broad inherited-risk assessment | The person diagnosed, or someone at risk | When a cancer looks like it runs in the family | Blood or saliva | Germline result with genetic counselling |
| Heritage Adhoc | Focused testing for named relatives | Relatives of someone with a known alteration | Once the family alteration is identified | Blood or saliva | A yes or no on one specific variant, with counselling |
What each service costs is discussed at a free consultation rather than published here, because the right tier depends on the question being asked and a bigger panel is not automatically the better one. Signal and the consultation itself are free, and we will tell you when a test would not change anything before you commit to it.
Choosing between them
The questions people actually ask
Sentinel or Clear?
Sentinel watches during active treatment: is this working, is resistance emerging. Clear watches after treatment given with curative intent: is anything left, is it coming back. Same technology, different question, different schedule.
Signature or Decipher?
Signature generates new sequencing. Decipher interprets sequencing that already exists. If you have been tested properly and recently, Decipher is usually the cheaper and faster route to the same answer.
Which Signature tier?
It depends on the question, not on the budget. A focused question about a well-defined driver may be answered by 33 genes. A complex case with few standard options is where 523 genes earns its cost. Our consultation exists to work that out honestly.
Heritage or Signature?
Heritage tests what you inherited, from blood or saliva, and the answer concerns your relatives as much as you. Signature tests what the tumour acquired. They answer different questions and one does not substitute for the other.
Blood or tissue?
Blood is easier and repeatable but depends on the tumour shedding enough DNA. Tissue is the conventional reference but needs an adequate sample and cannot be repeated casually. In several cancers the two are used together rather than sequentially.
Do I need any of this?
Sometimes not. In some cancers and at some stages, molecular profiling will not change what happens next, and we would rather tell you that at a free consultation than take your money to confirm it.
How they fit together
The shape of the journey
- At diagnosis, or a treatment changeBlueprint Care with a Signature test, or Decipher if sequencing already exists. This is the decision point, and the one where timing matters most.
- While treatment is runningSentinel, at two, four or six draws a year depending on how closely the situation needs watching.
- After treatment given with curative intentClear, on a schedule matched to the cancer type and the follow-up plan.
- Whenever inherited risk is raisedHeritage for the person diagnosed, then Heritage Adhoc for relatives once a family alteration is known.
- At any point, at no costSignal for a question, Navigation to organise records, and a free consultation to work out whether any of this applies.
Starting pointDecision points varyBeyond treatment
Stage 01 of 06
What do we actually know?
Interpret the evidence already available, reconcile the reports, and make the important unknowns visible before decisions build on incomplete information.
Next questionCreate a reliable starting point.
Stage 02 of 06
What additional biology matters?
Use molecular profiling when the next decision depends on a more precise view of the disease, rather than ordering every possible test. A bigger panel is not automatically the better one.
Next questionChoose the right level of evidence.
Stage 03 of 06
What should we discuss next?
Translate interpreted evidence into a decision-ready discussion: options, constraints, uncertainties, and the questions to put to the treating team.
Next questionMove from information to an informed plan.
Stage 04 of 06
What changes while treatment is underway?
Keep interpreting the evidence as treatment progresses and new results change the picture, rather than treating the original interpretation as permanently fixed.
Next questionRevisit the evidence as the situation evolves.
Stage 05 of 06
Has the picture changed?
At meaningful decision points, revisit the evidence when scans, progression, resistance, toxicity or new clinical information change the original assumptions.
Next questionReframe the next decision with current evidence.
Stage 06 of 06
What matters after the immediate treatment question?
Carry forward what remains useful beyond the immediate treatment phase, while new questions emerge around surveillance, family risk and future decisions.
Next questionKeep the pathway open to new questions.
Available at any point
Where can someone start?
Signal is a free entry point for a question, a report, or a second look. It is not tied to one stage of the pathway, and it costs nothing.
Next questionAvailable throughout the journey.
Available at any point
What if the next step is still unclear?
A free consultation creates space to frame the question, understand what is missing, and decide what kind of work is actually appropriate. Sometimes the answer is that no test would change anything, and we will say so.
Next questionAvailable throughout the journey.
Illustrative. People enter at different points, skip stages, or revisit an earlier question as evidence changes. No duration or sequence is implied.
Stated plainly
What none of these do
What we DO
- Tell you what is present, how strong the evidence is, and who signed for it
- State the limits of the method used, including what it could not have detected
- Map every recommendation to biosimilars, assistance programmes and schemes in India
- Say when a test would not change anything, before you pay for it
What we DON’T do
- Diagnose, prescribe, or replace your treating oncologist
- Let software have the final word on anything clinically consequential
- Guarantee a drug is available, approved, affordable or effective for you
- Rule out disease on the strength of a “not detected” result
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal